Actinium Pharmaceuticals financials
$1.14−3.39%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $35.0M | $0.00 | $0.00 | $90.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $81.0K | $0.00 |
| Gross profit | $35.0M | $0.00 | $0.00 | $90.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $81.0K | $0.00 |
| Gross margin | 100.0% | — | — | 100.0% | — | — | — | — | — | — | 100.0% | — |
| Operating income | $27.6M | -$5.9M | -$6.4M | -$5.7M | -$7.5M | -$16.6M | -$7.5M | -$12.6M | -$12.4M | -$9.6M | -$10.3M | -$14.4M |
| Net income | $27.9M | -$5.5M | -$5.9M | -$5.1M | -$6.9M | -$15.9M | -$6.7M | -$11.6M | -$11.4M | -$8.7M | -$9.3M | -$13.3M |
| Net margin | 79.7% | — | — | −5701.1% | — | — | — | — | — | — | −11511.1% | — |
| Diluted EPS | $0.89 | $-0.18 | $-0.19 | $-0.16 | $-0.22 | $-0.51 | $-0.21 | $-0.37 | $-0.38 | $-0.31 | $-0.34 | $-0.49 |
| EBITDA | $28.0M | -$5.9M | -$6.9M | -$5.5M | -$7.1M | -$16.6M | -$7.9M | -$12.4M | -$12.2M | -$9.4M | -$10.7M | -$14.2M |
| Operating cash flow | -$5.2M | -$5.9M | -$5.3M | -$6.3M | -$5.4M | -$7.6M | -$5.8M | -$12.0M | -$8.0M | -$7.4M | -$7.5M | -$11.1M |
| Free cash flow | -$5.7M | -$5.9M | -$5.4M | -$6.3M | -$5.4M | -$7.6M | -$5.8M | -$12.0M | -$8.0M | -$7.4M | -$7.5M | -$11.2M |
| Diluted shares | 31.4M | 31.2M | 31.2M | 31.2M | 31.2M | 31.2M | 31.2M | 31.1M | 30.1M | 27.9M | 27.4M | 27.1M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $36.5M | $42.1M | $48.0M | $53.4M | $59.9M | $65.3M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $5.0K | $8.0K | $11.0K | $13.0K | $16.0K | $18.0K |
| Total assets | $40.2M | $45.4M | $51.8M | $56.2M | $63.0M | $68.6M |
| Total liabilities | $9.9M | $43.1M | $43.9M | $42.4M | $44.0M | $43.0M |
| Shareholders' equity | $30.3M | $2.3M | $7.8M | $13.8M | $19.0M | $25.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology